Begin main content

Cabozantinib for Advanced Renal Cell Carcinoma – Details

Project Number pCODR 10123
Brand Name TBD
Generic Name Cabozantinib
Tumour Type Genitourinary
Indication Advanced Renal Cell Carcinoma (RCC)
Funding Request For the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior therapy
Review Status Open for Input on Submission
Pre Noc Submission Yes
NOC Date
Manufacturer Ipsen Biopharmaceuticals Canada Inc.
Submitter Ipsen Biopharmaceuticals Canada Inc.
Submission Date October 6, 2017
Submission Deemed Complete October 16, 2017
Submission Type New Drug
Prioritization Requested Requested
Stakeholder Input Deadline ‡ October 23, 2017
Check-point meeting (target date)
pERC Meeting (target date)
Clarification The Submitter notified pCODR that they will be unable to submit by their original target date and an updated target submission date has been provided.
Initial Recommendation Issued (target date)
Feedback Deadline (target date) ‡
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.